Charles Schwab Investment Management Inc Kiniksa Pharmaceuticals, Ltd. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$17.63 - $21.74 $1.28 Million - $1.58 Million	-72,586 Reduced 46.31%	84,155 $1.66 Million
Q4 2023 Feb 06, 2024	SELL	$14.37 - $19.07 $721,977 - $958,114	-50,242 Reduced 24.27%	156,741 $2.75 Million
Q3 2023 Nov 08, 2023	SELL	$13.62 - $20.2 $164,856 - $244,500	-12,104 Reduced 5.52%	206,983 $3.6 Million
Q2 2023 Aug 09, 2023	BUY	$10.44 - $16.48 $12,528 - $19,776	1,200 Added 0.55%	219,087 $3.08 Million
Q1 2023 May 11, 2023	BUY	$10.7 - $15.79 $131,931 - $194,690	12,330 Added 6.0%	217,887 $2.34 Million
Q4 2022 Feb 13, 2023	BUY	$11.42 - $17.05 $12,070 - $18,021	1,057 Added 0.52%	205,557 $3.08 Million
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $1.18 Million - $1.62 Million	120,997 Added 144.9%	204,500 $2.63 Million
Q2 2022 Aug 15, 2022	BUY	$7.6 - $11.41 $48,799 - $73,263	6,421 Added 8.33%	83,503 $810,000
Q1 2022 May 13, 2022	BUY	$9.3 - $12.37 $5,821 - $7,743	626 Added 0.82%	77,082 $767,000
Q4 2021 Feb 11, 2022	BUY	$10.39 - $15.15 $23,751 - $34,632	2,286 Added 3.08%	76,456 $900,000
Q3 2021 Nov 16, 2021	BUY	$11.39 - $16.23 $44,124 - $62,875	3,874 Added 5.51%	74,170 $845,000
Q2 2021 Aug 16, 2021	BUY	$13.22 - $19.09 $64,117 - $92,586	4,850 Added 7.41%	70,296 $980,000
Q1 2021 May 17, 2021	SELL	$16.68 - $23.97 $6,154 - $8,844	-369 Reduced 0.56%	65,446 $1.21 Million
Q4 2020 Feb 16, 2021	SELL	$14.8 - $21.15 $1,568 - $2,241	-106 Reduced 0.16%	65,815 $1.16 Million
Q3 2020 Nov 13, 2020	BUY	$15.21 - $25.53 $287,073 - $481,853	18,874 Added 40.12%	65,921 $1.01 Million
Q2 2020 Aug 14, 2020	BUY	$15.08 - $26.0 $174,189 - $300,326	11,551 Added 32.54%	47,047 $1.2 Million
Q1 2020 May 15, 2020	BUY	$11.0 - $19.76 $55,616 - $99,906	5,056 Added 16.61%	35,496 $550,000
Q4 2019 Feb 07, 2020	SELL	$5.24 - $12.96 $31,251 - $77,293	-5,964 Reduced 16.38%	30,440 $337,000
Q3 2019 Nov 08, 2019	BUY	$8.15 - $15.88 $3,186 - $6,209	391 Added 1.09%	36,404 $310,000
Q2 2019 Aug 09, 2019	BUY	$13.2 - $20.39 $158,677 - $245,108	12,021 Added 50.1%	36,013 $488,000
Q1 2019 May 14, 2019	BUY	$15.93 - $26.59 $144,835 - $241,756	9,092 Added 61.02%	23,992 $434,000
Q3 2018 Nov 13, 2018	BUY	$13.23 - $30.93 $197,127 - $460,857	14,900 New	14,900 $380,000

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

Pictet Asset Management Sa Geneva 73, V8

1.52M
Shares

$33.1 Million
0.03% of portfolio
Spearhead Capital Advisors, LLC Wellington, FL

203K
Shares

$4.42 Million
2.82% of portfolio
Harbor Capital Advisors, Inc.

97.5K
Shares

$2.13 Million
0.11% of portfolio
Putnam Investments LLC Boston, MA

39.5K
Shares

$860,794
0.0% of portfolio
Birchview Capital, LP Burlington, VT

30K
Shares

$654,000
0.69% of portfolio

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account